Related Experiment Video
Updated: Sep 26, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer
Xin-Hua Wang1, Jing Zhang1, Jie Wu1
1Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Abstract:
Male occult triple-negative breast cancer (TNBC) is an exceedingly rare form of breast cancer, and prospective information regarding its management is therefore lacking. Current treatment strategies are largely extrapolated from clinical trials of female breast cancer, leading to substantial knowledge gaps concerning the optimal management of male breast cancer. Here, we present a male patient with occult TNBC who responded to immunotherapy, with an obvious reduction in his tumor burden following antiandrogen therapy, after heavy treatment with several lines of chemotherapy. This case highlights the potential efficacy of immunotherapy in cases of male TNBC and suggests a role for antiandrogen therapy in managing patients with luminal androgen receptor-positive TNBC.
Insights
Male triple-negative breast cancer (TNBC) is rare, with limited management data. This case shows immunotherapy and antiandrogen therapy may effectively treat male TNBC, especially with androgen receptor positivity.
Area of Science:
- Oncology
- Male Breast Cancer Research
Background:
- Male triple-negative breast cancer (TNBC) is rare, lacking dedicated prospective management studies.
- Current treatment guidelines are primarily based on female breast cancer trials, creating knowledge gaps for male patients.
Observation:
- A male patient with occult TNBC received multiple chemotherapy lines.
- Following chemotherapy, the patient was treated with immunotherapy and antiandrogen therapy.
Findings:
- The patient exhibited a significant reduction in tumor burden.
- Response was observed with immunotherapy and antiandrogen therapy, particularly in the context of luminal androgen receptor-positive TNBC.
Implications:
- This case suggests immunotherapy holds potential efficacy for male TNBC.
- Antiandrogen therapy may be a viable treatment option for male TNBC patients with luminal androgen receptor-positive tumors.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019